Comparative Pharmacology
Head-to-head clinical analysis: BRIMONIDINE TARTRATE AND TIMOLOL MALEATE versus TRASICOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRIMONIDINE TARTRATE AND TIMOLOL MALEATE versus TRASICOR.
BRIMONIDINE TARTRATE AND TIMOLOL MALEATE vs TRASICOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brimonidine tartrate is a selective alpha-2 adrenergic receptor agonist that reduces aqueous humor production and increases uveoscleral outflow. Timolol maleate is a non-selective beta-adrenergic receptor antagonist that decreases aqueous humor production by blocking beta-2 receptors in the ciliary epithelium.
Non-selective beta-adrenergic antagonist with intrinsic sympathomimetic activity (partial agonist) at beta-1 and beta-2 receptors, reducing heart rate, myocardial contractility, and blood pressure.
One drop in the affected eye(s) twice daily (approximately 12 hours apart).
20-40 mg orally three times daily, increased to 80-160 mg daily if needed; maximum 320 mg/day.
None Documented
None Documented
Brimonidine: ~2.9 hours (terminal) after ophthalmic administration. Timolol: ~4 hours (terminal); clinically, systemic exposure is low due to topical route.
Terminal elimination half-life is approximately 8-12 hours in patients with normal renal function; may be prolonged in renal impairment, requiring dose adjustment.
Brimonidine: ~74% renal (unchanged and metabolites), ~22% fecal. Timolol: ~20% renal (unchanged), ~80% hepatic metabolism with biliary and fecal elimination.
Renal excretion of unchanged drug and metabolites accounts for approximately 80% of elimination, with about 20% appearing as unchanged drug; biliary/fecal excretion accounts for the remaining 20%.
Category A/B
Category C
Beta-Blocker
Beta-Blocker